Publications en collaboration avec des chercheurs de Hospital General Universitario de Valencia (11)

2025

  1. External validation of a prediction model for bleeding events in anticoagulated cancer patients with venous thromboembolism (PredictAI)

    Clinical and Translational Oncology, Vol. 27, Núm. 10, pp. 4031-4039

  2. MDM2 amplification in a real-world cohort of patients with biliary tract cancer from the Spanish RETUD gastrointestinal registry

    ESMO Gastrointestinal Oncology, Vol. 8

  3. Tinzaparin for the prevention of thromboembolic events in ambulatory patients with metastatic colorectal cancer receiving first line treatment: a randomised, clinical trial design

    BMC Cancer, Vol. 25, Núm. 1

2024

  1. Validation of the CoVID-TE model as a tool to predict thrombosis, bleeding, and mortality in the oncology patient with Sars-Cov-2 infection: a study by the SEOM cancer and thrombosis group

    Clinical and Translational Oncology, Vol. 26, Núm. 1, pp. 171-177

2023

  1. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

  2. Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group

    Clinical and Translational Oncology, Vol. 25, Núm. 10, pp. 3021-3031

2021

  1. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

2020

  1. High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1

    European Journal of Cancer, Vol. 141, pp. 193-198

2018

  1. Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer

    European Respiratory Journal

2015

  1. Erratum: Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study [Support Care Cancer, DOI 10.1007/s00520-015-2809-3]

    Supportive Care in Cancer

  2. Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study

    Supportive Care in Cancer, Vol. 23, Núm. 9, pp. 2833-2840